The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Who is this study for? Patients up to age 40 with sclerosing cholangitis and biliary atresia
What treatments are being studied? Oral Vancomycin
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 14 days
Maximum Age: 40
Healthy Volunteers: t
View:
• Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.
• Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.
Locations
United States
California
Sacramento Pediatric Gastroenterology
RECRUITING
Sacramento
Time Frame
Start Date: 2010-07
Estimated Completion Date: 2028-07
Participants
Target number of participants: 200
Treatments
Experimental: Oral Vancomycin
Every participant with PSC or BA will received the same Arm of Oral Vancomycin
Related Therapeutic Areas
Sponsors
Leads: Sacramento Pediatric Gastroenterology